| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2017-09-09 03:10:40 UTC |
|---|
| Update Date | 2022-11-30 19:25:59 UTC |
|---|
| HMDB ID | HMDB0114950 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | PA(18:2(9Z,12Z)/16:1(9Z)) |
|---|
| Description | PA(18:2(9Z,12Z)/16:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:2(9Z,12Z)/16:1(9Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of palmitoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. |
|---|
| Structure | [H][C@@](COC(=O)CCCCCCC\C=C/C\C=C/CCCCC)(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCC InChI=1S/C37H67O8P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-36(38)43-33-35(34-44-46(40,41)42)45-37(39)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h11,13-14,16-18,35H,3-10,12,15,19-34H2,1-2H3,(H2,40,41,42)/b13-11-,16-14-,18-17-/t35-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 1-Linoleoyl-2-palmitoleoyl-sn-glycero-3-phosphate | HMDB | | 1-Linoleoyl-2-palmitoleoyl-sn-phosphatidic acid | HMDB | | PA(18:2/16:1) | HMDB | | PA(18:2N6/16:1N7) | HMDB | | PA(18:2W6/16:1W7) | HMDB | | PA(34:3) | HMDB | | Phosphatidic acid(18:2(9Z,12Z)/16:1(9Z)) | HMDB | | Phosphatidic acid(18:2/16:1) | HMDB | | Phosphatidic acid(18:2n6/16:1n7) | HMDB | | Phosphatidic acid(18:2W6/16:1W7) | HMDB | | Phosphatidic acid(34:3) | HMDB | | Phosphatidate(18:2(9Z,12Z)/16:1(9Z)) | HMDB | | Phosphatidate(18:2/16:1) | HMDB | | Phosphatidate(18:2N6/16:1N7) | HMDB | | Phosphatidate(18:2W6/16:1W7) | HMDB | | Phosphatidate(34:3) | HMDB | | 1-linoleoyl-2-palmitoleoyl-sn-glycero-3-phosphate | SMPDB, HMDB | | 1-linoleoyl-2-palmitoleoyl-sn-phosphatidic acid | SMPDB, HMDB | | PA(18:2/16:1) | SMPDB, HMDB | | PA(18:2n6/16:1n7) | SMPDB, HMDB | | PA(18:2w6/16:1w7) | SMPDB, HMDB | | PA(34:3) | SMPDB, HMDB | | Phosphatidic acid(18:2(9Z,12Z)/16:1(9Z)) | SMPDB, HMDB | | Phosphatidic acid(18:2/16:1) | SMPDB, HMDB | | Phosphatidic acid(18:2n6/16:1n7) | SMPDB, HMDB | | Phosphatidic acid(18:2w6/16:1w7) | SMPDB, HMDB | | Phosphatidic acid(34:3) | SMPDB, HMDB | | Phosphatidate(18:2(9Z,12Z)/16:1(9Z)) | SMPDB, HMDB | | Phosphatidate(18:2/16:1) | SMPDB, HMDB | | Phosphatidate(18:2n6/16:1n7) | SMPDB, HMDB | | Phosphatidate(18:2w6/16:1w7) | SMPDB, HMDB | | PA(18:2(9Z,12Z)/16:1(9Z)) | SMPDB |
|
|---|
| Chemical Formula | C37H67O8P |
|---|
| Average Molecular Weight | 670.909 |
|---|
| Monoisotopic Molecular Weight | 670.457356115 |
|---|
| IUPAC Name | [(2R)-2-[(9Z)-hexadec-9-enoyloxy]-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propoxy]phosphonic acid |
|---|
| Traditional Name | (2R)-2-[(9Z)-hexadec-9-enoyloxy]-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propoxyphosphonic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H][C@@](COC(=O)CCCCCCC\C=C/C\C=C/CCCCC)(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCC |
|---|
| InChI Identifier | InChI=1S/C37H67O8P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-36(38)43-33-35(34-44-46(40,41)42)45-37(39)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h11,13-14,16-18,35H,3-10,12,15,19-34H2,1-2H3,(H2,40,41,42)/b13-11-,16-14-,18-17-/t35-/m1/s1 |
|---|
| InChI Key | NMJFHXZUKCNQMH-AXXPJHFTSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 1,2-diacylglycerol-3-phosphates. These are glycerol-3-phosphates in which the glycerol moiety is bonded to two aliphatic chains through ester linkages. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Glycerophospholipids |
|---|
| Sub Class | Glycerophosphates |
|---|
| Direct Parent | 1,2-diacylglycerol-3-phosphates |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1,2-diacylglycerol-3-phosphate
- Fatty acid ester
- Monoalkyl phosphate
- Dicarboxylic acid or derivatives
- Fatty acyl
- Alkyl phosphate
- Phosphoric acid ester
- Organic phosphoric acid derivative
- Carboxylic acid ester
- Carboxylic acid derivative
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Carbonyl group
- Organooxygen compound
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Naturally occurring processBiological processBiochemical pathwayMetabolic pathway- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/18:2(9Z,12Z)/16:1(9Z)) (PathBank: SMP0071186)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0071192)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0071196)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z)) (PathBank: SMP0071201)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0071207)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0079502)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)) (PathBank: SMP0079504)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0079506)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/16:1(9Z)) (PathBank: SMP0094769)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)) (PathBank: SMP0094772)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0094778)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/18:2(9Z,12Z)/18:1(11Z)) (PathBank: SMP0071187)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0071191)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0071193)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z)) (PathBank: SMP0071205)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)) (PathBank: SMP0071206)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/18:2(9Z,12Z)/18:1(9Z)) (PathBank: SMP0079490)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/18:2(9Z,12Z)/18:2(9Z,12Z)) (PathBank: SMP0079491)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0079492)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0079501)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)) (PathBank: SMP0094773)
- Cardiolipin Biosynthesis CL(18:2(9Z,12Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)) (PathBank: SMP0079497)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/18:2(9Z,12Z)) (PathBank: SMP0024214)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/18:3(6Z,9Z,12Z)) (PathBank: SMP0024215)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0024216)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/22:2(13Z,16Z)) (PathBank: SMP0024217)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z)) (PathBank: SMP0024218)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0024219)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/18:3(9Z,12Z,15Z)) (PathBank: SMP0024220)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z)) (PathBank: SMP0024221)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0024222)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0024223)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0024224)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0024225)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/20:2(11Z,14Z)) (PathBank: SMP0033229)
- De Novo Triacylglycerol Biosynthesis TG(18:2(9Z,12Z)/16:1(9Z)/20:3(8Z,11Z,14Z)) (PathBank: SMP0033230)
|
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 8.54 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 31.7283 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.97 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 4811.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 434.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 319.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 230.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1028.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 1678.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 1152.5 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 248.9 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 3262.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 1071.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 2614.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1214.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 675.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 481.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 778.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 10.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| PA(18:2(9Z,12Z)/16:1(9Z)),1TMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)O[Si](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 4732.7 | Semi standard non polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),1TMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)O[Si](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 4189.5 | Standard non polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),1TMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)O[Si](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 5412.8 | Standard polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),2TMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 4692.1 | Semi standard non polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),2TMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 4155.6 | Standard non polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),2TMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 4658.7 | Standard polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),1TBDMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)O[Si](C)(C)C(C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 4960.5 | Semi standard non polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),1TBDMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)O[Si](C)(C)C(C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 4291.4 | Standard non polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),1TBDMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)O[Si](C)(C)C(C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 5397.8 | Standard polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),2TBDMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 5136.7 | Semi standard non polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),2TBDMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 4324.3 | Standard non polar | 33892256 | | PA(18:2(9Z,12Z)/16:1(9Z)),2TBDMS,isomer #1 | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCC | 4756.7 | Standard polar | 33892256 |
|
|---|